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Introduction
Despite advances in treatment, epithelial ovarian cancer remains 
the most lethal of all gynecologic malignancies. In 2011, there 
were an estimated 22,000 new cases with approximately 15,500 
deaths, making ovarian cancer the fifth most common cause 
of cancer-related death. Treatment for advanced ovarian cancer 
includes radical tumor cytoreductive surgery in combination 
with adjuvant chemotherapy. Unfortunately, the majority of ovar-
ian cancers are diagnosed at an advanced stage and while there 
have been modest improvements in overall 5-year survival, from 
30–50%, this trend does not apply to advanced-stage tumors 
which have only improved from 20–25% in the same timeframe.
Hereditary breast and ovarian cancer syndrome (HBOC) 
is attributed to germline mutations in the BRCA1 or BRCA2 
tumor suppressor genes. BRCA mutations may account for as 
many as 90% of hereditary ovarian cancers and approximately 
10% of all ovarian cancers.1-3 Women with BRCA1 mutations 
BRCa1 plays an important role in DNa damage and repair, homologous recombination, cell cycle regulation and apoptosis. 
BRCa-mutated ovarian cancer often presents at an advanced stage, however, tend to have better response to platinum-
based chemotherapy as compared with sporadic cases of epithelial ovarian cancer (eOC). In spite of this, most patients 
will develop a recurrence and eventually succumb to the disease. preclinical studies are currently investigating natural 
compounds and their analogs for tumor-directed targets in ovarian cancer. The aim of this study is to investigate whether 
the sTaT3 inhibitor hO-3867, a novel curcumin analog, has a therapeutic effect on BRCa1-mutated ovarian cancer. Our 
novel agent, hO-3867 and a commercial sTaT3 inhibitor, sTaTTIC, significantly inhibited BRCa-mutated ovarian cancer 
cells in vitro in a dose- and time-dependent manner. BRCa-mutated ovarian cancer cells treated with hO-3867 exhibited 
a significant degree of apoptosis with elevated levels of cleaved caspase-3, caspase-7 and paRp. hO-3867 treatment 
induced more reactive oxygen species (ROs) in BRCa-mutated cells compared with wild-type cells, however, there was 
no increased ROs when benign ovarian surface epithelial cells were treated with hO-3867. BRCa1-mutated cancer cells 
had higher expression of Tyrosine-phosphorylated sTaT3 (pTyr705) as compared with other sTaT proteins. Furthermore, 
treatment of these cells with hO-3867 resulted in decreased expression of pTyr705 and its downstream targets cyclin D1, 
Bcl-2 and survivin. In addition, overexpression of sTaT3 cDNa provided resistance to hO-3867-induced apoptosis. Our 
results show that hO-3867, a potent sTaT3 inhibitor, may have a role as a biologically targeted agent for BRCa1-mutated 
cancers either as an adjunct to cytotoxic chemotherapy or as a single agent.
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have a 40–50% cumulative lifetime risk of developing ovarian 
cancer (10–25% for BRCA2 mutations), a marked increase from 
the 1.3% lifetime risk in women who are not mutation carriers.4-8 
Both BRCA proteins are involved in DNA repair via homolo-
gous recombination (HR) and thus cells with deficient BRCA 
are unable to repair DNA double strand breaks by HR. This 
can result in genomic instability and a predisposition to malig-
nant transformation. Although patients with BRCA deficiency 
have similar histopathologic characteristics as sporadic ovarian 
cancers, the time-to-recurrence, response rates to chemotherapy 
and overall survival are significantly improved in advanced stage 
hereditary ovarian cancer patients.9,10 It is theorized that the same 
DNA repair deficiency in hereditary tumors confers the improved 
survival rates to BRCA-deficient patients as these tumors are less 
likely to repair DNA cross-links caused by chemotherapeutic 
agents such as cisplatin.11-14
Curcumin has been used as a dietary spice and been con-
sumed as a medicinal supplement for thousands of years. In 
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the proliferation of cells, but ultimately causes cell death, a series 
of experiments were performed to evaluate if HO-3867 induces 
apoptosis in BRCA1-mutated ovarian cancer cells. Figure 2A 
shows a western blot of control vs. HO-3867-treated cells. This 
figure demonstrates that treatment results in cleavage of caspase 
3, 7 and PARP, suggesting more cells are going through the apop-
totic pathway. These results correlated with the results of annexin 
V flow cytometry seen in Figure 2B. Seventy-five percent of cells 
treated with HO-3867 were shown to be in either early or late 
phase apoptosis compared with 12% of untreated cells, respec-
tively. We then wanted to show that HO-3867, while toxic to 
cancer cells, does relatively little harm to non-cancerous cells. 
Figure 2C and D shows the results of a ROS assay. For BRCA1-
mutated cells there was an increase in the number of ROS cor-
relating to DNA damage and eventual cell death compared with 
controls. However, in non-cancerous human ovarian surface epi-
thelial (hOSE) cells, this phenomenon was not seen. There was 
no difference in the amount of ROS staining seen between con-
trol and treatment groups in hOSE cells inferring that HO-3867, 
while damaging to cancer cells, may spare its harmful effects to 
non-cancerous cells. This was additionally confirmed using a 
subG1 analysis with flow cytometry (Fig. 2E). Again, hOSE cells 
showed no difference in the percent of cells in the subG1 phase, 
however in BRCA1-mutated cells, there was a significant increase 
in the number of cells treated with HO-3867 that were unable to 
continue through the cell cycle.
Expression of STAT proteins in BRCA1-mutated ovarian 
cancer cells. Previous studies have shown HO-3867 and other 
curcumin analogs exert their effects, at least in part, via inhibi-
tion of STAT proteins. In order to understand why HO-3867 
had a greater effect on BRCA1-mutated cells as compared with 
non-mutated EOC cells western blot analysis of various STAT 
proteins was performed. As seen in Figure 3A, there was minimal 
expression of pSTAT1 and pSTAT5 among all three cell lines. 
There was, however, a markedly higher expression of pSTAT3 
Tyr 705 (pTyr705) expression in BRCA1-mutated cells as com-
pared with A2780 and SKOV3 cells. Total STAT3 and a second 
phosphorylation site, pSTAT3 Ser727 (pSer727), were observed 
to be similarly expressed in all three cell lines. The striking dif-
ference of pTyr705 expression in BRCA1-mutated cells compared 
with the other ovarian cancer cell lines gives a possible reason 
for the difference seen when treated with a potent STAT inhibi-
tor. Figure 3B shows consistent expression of upstream proteins 
including TYK2, pJAK1 and JAK 2 in all cell lines. There was 
a decrease in the downstream negative regulator SOCS1, which 
may also play a role in treatment discrepancy.
HO-3867 inhibits STAT3 and downstream proteins. It was 
important to determine if HO-3867 alters protein expression 
of pTyr705 and cell-survival proteins downstream of the STAT 
pathway in BRCA1-mutated cells (Fig. 4A). After treatment 
with 10 μM of HO-3867 for 24 h, a significant decrease in the 
expression of pTyr705 was observed. Effects on downstream pro-
teins included decreased expression of cell proliferation and cell 
survival proteins (pAKT and cyclin D1) and apoptotic proteins 
(Bcl-2, Survivin). There was also an increase in the cell cycle reg-
ulator protein p21. Figure 4B shows the quantitative depiction of 
1949, curcumin was shown to be a biologically active compound 
with bactericidal attributes and more recently with anticancer 
properties. However, curcumin has poor bioavailability due 
to poor absorption, rapid metabolism and rapid elimination. 
Efforts have been made to improve curcumin’s bioavailability, 
for example, with the use of structural analogs.15 Recently, we 
developed a novel class of curcumin analogs, diarylidenyl piperi-
dones (DAP), which were developed by incorporating a piperi-
done link to the β-diketone structure and fluorosubstitutions on 
the phenyl groups.16-18 The DAP compounds, in general, were 
more effective than curcumin in inhibiting the proliferation of 
a variety of cancer cell lines.16 HO-3867, one of the DAP com-
pounds with ortho-fluorinated phenyl groups, exhibited potent 
anticancer efficacy in vitro when tested using ovarian epithelial 
cancer cell lines as well as in vivo using a mouse model.19 In 
this study, we investigated the effects of HO-3867 on the pro-
liferation and viability of BRCA1-deficient ovarian cancer cells. 
Specifically, we evaluated the production of reactive oxygen 
species (ROS) and induction of apoptosis in BRCA1-mutated 
ovarian cancer cells. Our results show that the curcumin analog 
HO-3867 rapidly and selectively induces ROS and inhibition of 
STAT3, resulting in suppression of cell proliferation and induc-
tion of apoptosis.
Results
Effect of STAT3 inhibitor on BRCA1-mutated ovarian cancer 
cell proliferation. To determine the effect of our novel STAT3 
inhibitor, HO-3867, on BRCA1-mutated ovarian cancer cell pro-
liferation and viability, cells were treated with increasing doses 
of HO-3867 (1, 5, 10 and 20 μM) for 24 h. Figure 1A shows 
results of a clonogenic assay on cells treated with HO-3867 and 
depicts a dose-dependent decrease in the percentage of colonies 
formed. At 10 μM, a greater than 80% reduction in the number 
of colonies was observed. Figure 1B shows the effect of HO-3867 
on the total number of cells after various time points of treatment 
with increasing doses of HO-3867. After 48 h incubation with 
10 μM of HO-3867, there was a 9-fold decrease in the number of 
BRCA1-mutated cells when compared with controls. At 20 μM, 
90% of cells were non-viable after 24 h incubation and no cells 
remained viable at 48 h. Next, control and treated cells grown on 
glass coverslips were stained with DAPI to confirm a decrease in 
proliferation. Figure 1C shows untreated cells with normal pro-
liferative staining as compared with cells treated with HO-3867, 
which had markedly decreased staining. Figure 1D shows results 
of a MTT viability assay of four ovarian cancer cell lines, A2780, 
A2780R, SKOV3 and BRCA1-mutated cells. While cell viability 
is decreased in all four cell lines, the most marked reduction was 
in BRCA1 cells. Following this, BRCA cells were then treated 
with HO-3867, cisplatin, ABT (a commercial PARP inhibitor), 
curcumin or STATTIC (a commercial STAT3 inhibitor). There 
was a significant decrease with all treatments, however, the most 
pronounced was with HO-3867 which appeared to be more effec-
tive than STATTIC, a known potent STAT3 inhibitor (Fig. 1E).
HO-3867 induces apoptosis in BRCA1-mutated ovarian 
cancer cells. To determine whether HO-3867 not only decreases 
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with STAT3 cDNA prior to treatment with HO-3867. Results 
seen in Figure 4C show that cells transfected with STAT3 
cDNA had increased viability compared with non-transfected 
average levels of expression between control and treated cells for 
pTyr705 and Bcl-2. In order to determine if decreased cell viabil-
ity was truly from inhibition of STAT3, cells were transfected 
Figure 1. hO-3867 inhibits BRCa1 ovarian cancer cell proliferation. (a) Clonogenic assay of BRCa1-mutated ovarian cancer cells treated with increas-
ing concentrations of hO-3867 for 24 h (1, 5, 10 and 20 μM). There is a significant decrease in the percentage of cell colonies in a dose response 
progression. (B) after treatment with increasing concentrations of hO-3867 (1, 5, 10 and 20 μM) at serially sequential times (12, 24 and 48 h) cells were 
collected and counted. Cell counts were significantly decreased starting with the 5 μM concentration. after 24 h treatment with 20 μM there were no 
viable cells remaining. (C) Conformation of decreased proliferation was performed with immunohistochemistry staining with DapI. This demonstrated 
that cells treated with 10 μM of hO-3867 showed a significant decrease in the number of proliferating cells. (D) MTT assay of four ovarian cancer cell 
lines (a2780, a2780R, sKOV3 and BRCa1-mutated cells) treated with hO-3867 or sTaTTIC. While all cell lines showed significant decreased viability, this 
was most observed in the BRCa1-mutated cells. (e) Of interest hO-3867 showed more of an effect than the potent sTaT3 inhibitor sTaTTIC. (e) MTT 
assay of BRCa1-mutated cells with different treatments [Curcumin, cisplatin (Cp), paRp-inhibitor (aBT), sTaTTIC and hO-3867]. While all treatments 
decreased cell viability the most dramatic effect was seen in the hO-3867 treatment group.
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Figure 2. For figure legend, see page 770.
cells treated with HO-3867. This infers that BRCA 1-mutated 
cells transfected with STAT3 cDNA acquired some resistance to 
HO-3867.
Effect of HO-3867 on BRCA1-mutated breast cancer cells. 
Finally, we looked at the effect HO-3867 had on other BRCA1-
mutated cancer cells, namely SUM 149, a breast cancer cell line. 
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apoptosis (Fig. 5C). These results indi-
cate that the STAT3 inhibitor-induced 
apoptosis in the BRCA1 cells is not 
mediated by p53.
Discussion
Our novel anticancer agent HO-3867 
has been shown to be a potent STAT3 
inhibitor with anticancer proper-
ties. This is the first report showing 
HO-3867 and STATTIC, another 
potent STAT3 inhibitor, significantly 
suppresses BRCA1-mutated ovarian 
cancer cell proliferation and viability. 
This study furthermore demonstrates 
that HO-3867 selectively induces ROS 
and apoptosis in BRCA1-mutated 
human ovarian cancer cells in vitro. 
We have shown that pSTAT3 is highly 
expressed in BRCA1-mutated can-
cer cells compared with other STAT 
proteins. Our compound, HO-3867, 
inhibits BRCA1-mutated cancer cell 
proliferation and survival by target-
ing STAT3 pathways and altering the 
expression of pro-survival proteins 
cyclin D1, Bcl-2 and survivin.
Tumor cells typically exhibit 
increased levels of intracellular ROS, 
which in turn induce various gene mutations leading to meta-
bolic malfunction and more ROS generation.20 Furthermore, 
ROS induces oxidative damage to proteins, lipids and other 
cellular components causing significant intracellular stress.20,21 
In this study, a proposed therapeutic strategy against BRCA1-
mutated ovarian cancer is to treat cancer cells with chemothera-
peutic agents that have pro-oxidant properties, which increase 
the intracellular ROS generation immensely in cancer cells with-
out harming normal cells. This hypothesis is supported by our 
recent findings that ROS-generating agents showed selective 
toxicity in tumor cells with increased ROS. Using EPR mea-
surements, we have previously observed that HO-3867 under-
went redox cycling to its corresponding nitroxide forms in vitro. 
We examined the role of the nitroxide moiety by comparing 
HO-3867 with its parent structure, H-4073. Cytotoxic effects of 
H-4073 and HO-3867 on A2780 cells were significantly higher 
compared with curcumin under similar conditions.16 However, 
SUM149 cells were treated for 12 and 24 h with 5 or 10 μM 
of HO-3867, 25 μM of STATTIC, or 10 μg/mL of cisplatin. 
Figure 5A shows the results of a MTT assay performed after treat-
ment. A decrease in viability was seen in all treatments at both 
time points. While STATTIC showed the largest decrease in via-
bility at 12 h, by 24 h, all treatments showed a 50–60% decrease 
in viability. In order to determine if HO-3867 had a similar effect 
on cell death in SUM 149 cells as with the ovarian cell popu-
lation, an Annexin assay was performed. Treatment with either 
10 μM of HO-3867 or 25 μM STATTIC for 24 h showed a sig-
nificant increase in apoptosis vs. controls (> 95 vs. 18.2%) as seen 
in Figure 5B. Further, we determine whether or not the STAT3 
inhibitor-induced apoptosis was dependent on p53, BRCA1 can-
cer cells were pretreated with pifithrin (pifithrin; Sigma) for 1 h 
and then treated with HO-3867 and STATTIC for 24 h. The 
cells were analyzed for cell viability by MTT assay. Pretreatment 
with pifithrin did not block HO-3867 and STATTIC-induced 
Figure 2 (See previous  page). effect of hO-3867 on apoptosis in BRCa1 ovarian cancer cells. (a) Representative western blot showing a significant 
increase in cleaved caspase-3, -7 and cleaved paRp after treatment with hO-3867. (B) Flow cytometry with propidium iodide and annexin V. Treatment 
with hO-3867 showed a significant increase in the number of cells in apoptosis from controls (75.0 vs. 12.1%, respectively). Graphical representation 
of flow cytometry results shown. (C and D) Measurement of intracellular ROs in BRCa1-mutated cancer cells and normal hOse cells. at baseline there 
is an increased measure of ROs in BRCa1 cancer cells vs. controls. after treatment with 10 μM hO-3867 for 24 h, a significant increase in the number of 
cells with ROs was detected in BRCa1 cells. This observation, however, was not seen in hOse cells showing hO-3867 was selective against the BRCa1-
mutated cancer cell line while sparing normal, non-cancerous cells. (e) Graphical results from a subG1 analysis after treatment with hO-3867 for 24 h. 
after treatment, a significant increase in the number of BRCa1 cells remained in the subG1 phase.
Figure 3. activation of the sTaT pathway in BRCa1-mutated ovarian cancer cells. (a) BRCa1, a2780 
and sKOV3 cells were cultured and collected for western blot for expression of proteins in the sTaT 
family. There was minimal expression of sTaT1 or sTaT5 (a2780 cells minimally expressed sTaT5). all 
cell lines uniformily expressed sTaT3 and the activated form psTaT3 ser727, however, only BRCa1 
cells showed expression of psTaT3 Tyr705. (B) Representative western blots for protein expression 
in the sTaT3 pathway. BRCa1 cells showed less expression of TYK2 and sOCs1. Both pJaK1 and JaK2 
were consistently expressed in all lines.
D
ow
nl
oa
de
d 
by
 [P
TE
 Fe
lno
ttk
ep
ze
si 
Es
 E
mb
eri
] a
t 1
4:2
4 2
1 D
ec
em
be
r 2
01
4 
© 2012 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Cancer Biology & Therapy 771
cancer.23-26 The constitutively active STAT3 has been implicated 
in the induction of resistance to apoptosis, possibly through the 
expression of anti-apoptotic proteins and has recently become a 
proposed target for cancer therapy.27,28 This study is the first to 
show that, pTyr705 is highly expressed in BRCA1-mutated ovar-
ian cancer cells compared with somatic ovarian cancer cells. In 
addition, we have shown that expression of pTyr705 is necessary 
for BRCA1 cancer cell proliferation and survival. Further stud-
ies will be required to fully understand the mechanistic role of 
STAT3 expression in BRCA1 ovarian cancer cells and its role in 
regulation of cell proliferation and survival.
Recently, STAT3 has attracted much attention as a pharmaco-
logic target. Several reports have demonstrated that inhibition of 
while H-4073 significantly reduced cell viability in hOSE cells, 
HO-3867 had no significant effect. Our results indicate that 
HO-3867 selectively drives ovarian cancer cells with a BRCA1-
mutation to undergo apoptosis while sparing non-cancerous 
cells. Rational drug combinations that target matching specific 
and vital targets may kill cancer cells selectively.22
In this study we also investigated the role of STAT3 in 
BRCA1-mutated ovarian cancer cells and the effect of HO-3867 
on STAT3 activation and related proteins. STAT3 has a wide 
variety of biological functions, including acceleration of cell pro-
liferation and activation of anti-apoptotic proteins such as Bcl-X
L
, 
Bcl-2, Mcl-1, c-Myc and Survivin. STAT3 is constitutively acti-
vated in a variety of tumor cell types including breast and ovarian 
Figure 4. effect of hO-3867 on sTaT pathway protein expression. (a) BRCa1 cells were treated with 10 μM of hO3867 for 24 h and protein expres-
sion analyzed via western blot. There was a significant decrease in the expression of activated psTaT3 Tyr705, the downstream prosurvival protein 
and Cyclin D1, as well as anti-apoptotic proteins Bcl-2 and survivin. Increased expression of the cell cycle regulator p21 was seen as well. (B) Graphical 
representation confirms decrease of psTaT3705 and Bcl-2 expression after treatment with 10 μM hO-3867 for 24 h. (C) sTaT3 overexpression leads to 
hO-3867 resistance. BRCa1-mutated cells were transfected with sTaT3 cDNa to see if overexpression of sTaT3 could lead to resistance of hO-3867 on 
cell viability. Cells that were treated with 10 μM of hO-3867 with only the lipofectamine vector showed identical loss in cell viability as cells treated 
with hO-3867 alone. however, hO-3867-treated cells that were transfected with sTaT3 cDNa had a significant increase in viability from those cells that 
were not transfected. although there was improved survival there was still a significant decrease in viability from control cells showing the potency of 
hO-3867 as a sTaT inhibitor.
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We found that the levels of both Bcl-2 and Bcl-x
L
 were 
decreased with a corresponding increase in cleaved caspase-3 
and -7 in BRCA1-mutated cancer cells treated with HO-3867. In 
addition we confirmed that overexpression of STAT3 led to resis-
tance to HO-3867, suggesting that STAT3 was a critical target of 
HO-3867 in BRCA1 ovarian cancer cells.
Results from this pilot study indicate that there is a role for 
STAT3 in BRCA1-mutated ovarian cancer cell survival and 
STAT3 by flavonoids and synthetic compounds results in cancer 
cell apoptosis both in vitro and in vivo.29,30 HO-3867 inhibits 
STAT3 and STAT3-regulated anti-apoptotic genes such as Bcl-2 
and Bcl-X
L
, contributing to decreased cancer cell survival via 
induction of apoptosis. Previous studies have shown that mem-
bers of the Bcl-2 family play a key role in regulating caspase acti-
vation during apoptosis31 and that Bcl-2 and Bcl-x
L
 are negative 
regulators of caspase activation.32,33
Figure 5. effect of hO-3867 on viability and apoptosis in BRCa1-mutated breast cancer cells. (a) MTT assay of BRCa1-mutated breast cancer cell line 
(sUM149) treated with 5 or 10 μM hO-3867, 25 μM sTaTTIC or 10 μg/mL cisplatin for 12 or 24 h. Cells showed a significant decreased in viability as 
early as 12 h. By 24 h all treatments decreased viability by 50–60%. (B) Flow cytometry with propidium iodide and annexin V. Treatment with 10 μM 
hO-3867 and 25 μM sTaTTIC showed a significant increase in the number of cells in apoptosis from controls (96.3 and 99% vs. 18.2%, respectively). 
Graphical representation of flow cytometry results shown. (C) Inhibition of p53 by pifithrin (pF) did not reverse the sTaT3 inhibitor induced apoptosis. 
BRCa1 mutated ovarian cancer cells were pretreated with the pifithrin 10, 25 and 50 μM for 1 h and then treated with hO-3867 and sTaTTIC for 24 h. 
Cell viability was analyzed by MTT assay. sTaTTIC data not shown.
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60 mm culture dishes and cultured for 24 h. After 24 h the cells 
were treated with varying concentrations (1, 5, 10 and 20 μM) of 
HO-3867 and counted using a NucleoCounter (New Brunswick 
Scientific) at 12, 24 or 48 h of treatment.
Cell viability by MTT assay. Cell viability was determined 
by a colorimetric assay using MTT. In the mitochondria of 
living cells, yellow MTT undergoes a reductive conversion to 
formazan, giving a purple color. A2780, A2780R, SKOV3 and 
BRCA1-mutated ovarian cancer cells were grown to 80% con-
fluence in 75 mm flasks, trypsinized, counted and seeded in 
96-well plates with an average population of 7,000 cells/well. 
The cells were then incubated overnight and then treated with 
either STATTIC 25 μM or HO-3867 10 μM for 24 h. Cell 
viability was then calculated. Similarly, BRCA1-mutated cells 
were treated with curcumin 100 μM, cisplatin 10 μg/mL, ABT, 
STATTIC 25 μM or HO-3867 10 μM for 24 h and cell via-
bility analyzed. The dose and time of incubation were deter-
mined from a set of preliminary experiments. All experiments 
were done using six replicates and repeated at least three times. 
Cell viability was expressed as a percentage of MTT viability of 
untreated cells.
Western blotting. A2780, SKOV3 and BRCA1-mutated 
ovarian cancer cells were incubated in their respective media. 
Cell lysates were prepared in non-denaturing lysis buffer 
[10 mM TRIS-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 
1 mM EDTA, 1 mM EGTA, 0.3 mM phenylmethylsulfonyl 
fluoride, 0.2 mM sodium orthovanadate, 0.5% NP40, apro-
tinin (1 μg/ml) and leupetin]. Cell lysates were centrifuged at 
12,000 rpm for 20 min at 4°C and the supernatant was sepa-
rated. The protein concentration in the lysates was determined 
using a Pierce detergent-compatible protein assay kit. For west-
ern blotting, 25–50 μg of protein lysate per sample was dena-
tured in 2x sample buffer and subjected to SDS-PAGE on a 
10% or 12% tris-glycine gel. The separated proteins were trans-
ferred to a PVDF membrane and then blocked with 5% non-
fat milk powder (w/v) in TBST (10 mM Tris, 100 mM NaCl, 
0.1% Tween 20) for 1 h at room temperature or overnight at 
4°C. The membranes were incubated with the primary antibod-
ies described above. The bound antibodies were detected with 
horseradish peroxidase (HRP)-labeled sheep anti-mouse IgG 
or HRP-labeled donkey anti-rabbit IgG (Amersham) using an 
enhanced chemiluminescence detection system (ECL Advanced 
kit). Protein expressions were determined using Image Gauge 
version 3.45. The protocol was the same for cells treated with 
DMSO (control) or HO-3867 10 μM for 24 h. Equal volumes 
of DMSO (0.1% v/v) were present in both groups.
Apoptosis/flow cytometry. BRCA1-mutated ovarian cancer 
cells were treated with 10 μM of HO-3867 for 24 h. They were 
then trypsinized, washed in PBS and labeled with propidium 
iodide and Alexa Fluor 488 Annexin V using the Alexa Fluor 
488 Annexin V/Dead Cell Apoptosis Kit (Invitrogen). Apoptotic 
cells were measured by flow cytometry on a FACS Caliber (BD 
Bioscience).
Measurement of intracellular ROS. The ROS levels in cells 
treated with HO-3867 were determined using H2DCF-DA, 
a membrane-permeative fluorogenic probe. The acetate and 
proliferation. A decrease in cell survival was also seen in BRCA1-
mutated breast cancer cells, but the exact mechanism still needs 
to be elucidated. STAT3 inhibitors HO-3867 and STATTIC sig-
nificantly suppress cancer cells through the induction of ROS 
and inhibition of STAT3. An additional benefit of HO-3867 is 
the selective induction of ROS in cancer cells without damage to 
non-cancerous cells, which provides a considerable advantage as 
a selective chemotherapeutic agent for BRCA1-mutation carriers. 
Future studies must be done in vivo with mice bearing BRCA1 
mutations. Results from these studies will further validate our 
current findings and help decipher the role of STAT3 inhibitors 
at the clinical level.
Materials and Methods
Materials. HO-3867 was synthesized in the laboratory. Stock 
solutions of the compounds were freshly prepared in dimeth-
ylsulfoxide (DMSO). Cell-culture medium (RPMI 1640 and 
DMEM), fetal bovine serum (FBS), antibiotics, sodium pyru-
vate, trypsin, non-essential amino acids and phosphate-buff-
ered saline (PBS) were purchased from Gibco. Polyvinylidene 
fluoride (PVDF) membrane and molecular-weight markers 
were obtained from Bio-Rad. Antibodies against caspase 3, 
cleaved caspase 3, caspase 7, cleaved caspase 7, PARP, cleaved 
PARP, pSTAT1, pSTAT3 Tyr705, pSTAT3 Ser727, pSTAT5, 
TYK, pJak1 and pAKT were purchased from Cell Signaling 
Technology. Antibodies specific for STAT3, JAK2, SOCS1, 
Actin, cyclin D1, p21, Bcl-x
L
 and Bcl-2 were purchased from 
Santa Cruz Biotechnology. Enhanced chemiluminescence (ECL) 
reagents were obtained from Amersham Pharmacia Biotech (GE 
Healthcare). All other reagents, of analytical grade or higher, 
were purchased from Sigma-Aldrich.
Cell lines and cultures. A2780, A2780R, SKOV3, hOSE, 
SUM-149 and BRCA1-mutated human epithelial ovarian can-
cer cell lines were used in this study. The cells were grown in 
RPMI 1640, DMEM, F-12 Hams or MEBM/RPMI medium 
supplemented with 5 or 10% FBS, 2% sodium pyruvate, 1% 
penicillin and 1% streptomycin with or without insulin. Cells 
were grown in a 75 mm flask to 70% confluence at 37°C in an 
atmosphere of 5% CO
2
 and 95% air. Cells were routinely tryp-
sinized (0.05% trypsin/EDTA) and counted using an automated 
counter (NucleoCounter, New Brunswick Scientific).
Cell survival by clonogenic assay. Cell survival was assessed 
by clonogenic assay. Cells at ~80% confluence were trypsinized, 
rinsed, seeded onto 60-mm dishes (5 × 104 cells per dish), grown 
for 24 h at 37°C and treated afterward with increasing doses of 
HO-3867 (1, 5, 10 and 20 μM) for 24 h. Cells treated with equal 
amounts of DMSO alone served as controls. After treatment, 
the cells were washed twice with PBS, trypsinized, counted and 
plated in 60-mm dishes in triplicate and incubated for an addi-
tional 7 d. The colonies were then stained with crystal violet (in 
ethyl alcohol) and counted using an automated colony counter 
(ColCount, Oxford Optronix). Each experiment was repeated at 
least five times.
Cell proliferation. BRCA1-mutated ovarian cancer cells were 
cultured in MEBM/RPMI medium. They were seeded into 
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the use of an EPICS Profile II flow cytometer (Coulter Corp.). 
All experiments were performed in triplicate.
Transfection of wild-type STAT3 cDNA. The STAT3 
overexpression experiments were performed using a wild-type 
STAT3 cDNA. The FLAG-tagged gene was transfected into 
BRCA1-mutated ovarian cancer cells using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol. At 24 h 
after the transfection of the STAT3 gene, HO-3867 (10 μm) was 
added and incubated for 24 h. The cells were then subjected to a 
MTT viability assay.
Statistical analysis. Results were expressed as mean ± SE. 
Comparisons between groups were made by a Student’s t-test. 
The significance level was set at p ≤ 0.05.
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acetoxymethyl ester groups of this probe are enzymatically 
cleaved inside living cells. The probe can then be oxidized by 
intracellular oxidants to give a product, DCF, which emits 
a strong, green fluorescence (λex = 504 nm; λem = 529 nm). 
The fluorescence intensity is proportional to the level of cellular 
oxidants. Cells, grown to 80% confluence on 6-mm glass cov-
erslips, were treated with HO-3867 for 24 h followed by incuba-
tion with H2DCF-DA. The cells were further incubated in the 
dark for 20 min and washed with protein-free medium and then 
fluorescence images were immediately captured with a Nikon 
Eclipse TE2000-U camera system using excitation/emission at 
495/520 nm. The captured images were then analyzed using 
MetaMorph image analysis software.
Sub G
1
 analysis. BRCA1-mutated and hOSE cells were 
treated with 10 uM HO-3867 for 24 h. Cells were then trypsin-
ized, collected by centrifugation, resuspended in PBS and fixed 
in 70% ethanol at -20°C overnight. After centrifugation, the cells 
were then washed in PBS and resuspended in potassium iodide 
(PI)-staining solution (PBS, PI, RNase) (Boehringer Mannheim 
Antisense bcl-x
l
 546 and Chemotherapy Co.). Specimens were 
incubated in the dark for 30 min at 37°C and then analyzed with 
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